SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-23-242481
Filing Date
2023-09-26
Accepted
2023-09-26 16:16:08
Documents
12
Period of Report
2023-09-19
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d531637d8ka.htm   iXBRL 8-K/A 49739
  Complete submission text file 0001193125-23-242481.txt   178447

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20230919.xsd EX-101.SCH 2860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20230919_lab.xml EX-101.LAB 18702
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20230919_pre.xml EX-101.PRE 11702
6 EXTRACTED XBRL INSTANCE DOCUMENT d531637d8ka_htm.xml XML 4109
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38052 | Film No.: 231280640
SIC: 2834 Pharmaceutical Preparations